The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape.
 
Ali Shamseddine
Honoraria - AstraZeneca; Merck; MSD; MSD; SERVIER
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Amgen; Bayer; Merck; MSD; Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck
Travel, Accommodations, Expenses - Algorithm SAL; Amgen; Merck; MSD
 
Noura Abbas
No Relationships to Disclose
 
Walid Khaled Chatila
No Relationships to Disclose
 
Henry S. Walch
No Relationships to Disclose
 
Jordan Eichholz
No Relationships to Disclose
 
Nikolaus Schultz
No Relationships to Disclose
 
David B. Solit
Stock and Other Ownership Interests - Elsie Biotechnologies; Fore Biotherapeutics; Function Oncology; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Elsie Biotechnologies; Fog Therapeutics; Fore Biotherapeutics; Function Oncology; PAIGE.AI (I); Pfizer; Pyramid Biosciences; Rain Therapeutics; Scorpion Therapeutics; Vividion Therapeutics
 
Maya Charafeddine
No Relationships to Disclose
 
Monita Al Darazi
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Helio Health; Incyte; Ipsen; Merck Serono; Merus NV (I); Neogene Therapeutics (I); Newbridge Pharmaceuticals; Novartis (I); QED Therapeutics; Roche/Genentech; SERVIER; Tempus (I); Thetis Pharma (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Flare Therapeutics; Janssen Biotech; PAIGE.AI